Nutriband is primarily engaged in the development of a portfolio of transdermal(delivered through the skin) pharmaceutical products.
Our lead product is our AVERSA technology. AVERSA™ abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential specifically Opioids. Our first application for AVERSA is for our abuse deterrent fentanyl transdermal patch which we are developing to provide clinicians and patients with an extended release chronic pain relief. The goal is to make these pain treatments safe for all who need them. When used correctly they provide incredible relief and care to chronic pain patients.
It is our belief that our abuse deterrent technology can be broadly applied to various transdermal products and our strategy is to follow the development of our abuse deterrent fentanyl transdermal system with the development of additional transdermal prescription products for pharmaceuticals that have risks or a history of abuse. Nutriband has assembled an experienced team striving to improve the safety of abuseable drugs such as opioid based medications. In addition, we are developing a portfolio of transdermal pharmaceutical products to deliver commercially available drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes. The goal for Nutriband is to improve the safety, comfort and efficacy of approved drugs through incorporating transdermal technology’s.
Nutriband acquired 4P Therapeutics on August 1, 2018.
As a result of the acquisition, the focus of our business changed from the development and marketing of consumer transdermal products to the development of 4P Therapeutics’ portfolio of pharmaceutical transdermal products, with our lead product being the abuse deterrent fentanyl transdermal system.
Our AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with Patent prosecution in the United States and Canada. We have made sure to target all large applicable markets and our Global patent protection has opened up many opportunities for Nutriband to make a big impact on the safety profile of drugs globally.
Nutriband acquired Pocono Pharma on December 1, 2020.